Saturday, April 2, 2022

French CMO Fareva adds 4 facilities, more than 1,000 employees in Euro growth spurt


Despite COVID-19 uncertainty, the market for contract pharmaceutical manufacturing continues to grow, and some midlevel players are looking to expand. Now, a French CMO is looking to scale up in its home country and abroad to keep up with demand.

Fareva plans to bolt on four manufacturing sites across France and Austria to boost its sterile injectable and monoclonal antibody production. The new facilities will bring more than 1,000 employees into the fold, the company said.

Of those four sites, Fareva has finalized terms for two—at Idron and Saint-Julien-en-Genevois in France—with French pharma firm Pierre-Fabre Group. Financial terms of the deal were not disclosed.

Free Webinar

Hindsight is so 2020 – Getting Ahead of CNS Trial Enrollment in a Rapidly Changing Clinical Landscape

The past six months have highlighted both existing and unexpected enrollment challenges, as sponsors, CROs, and sites have been pressed to evolve their recruitment strategies. Join us as Rho experts discuss their approach to adapting CNS trial enrollment to a rapidly changing clinical landscape. Register now.

The Idron “pilot plant” holds 200 employees and 10 commercial lines dedicated to sterile injectables, Fareva said, and will go online at the end of 2021. The smaller Saint-Julien-en-Genevois site employs more than 30 workers and specializes in producing monoclonal antibodies.

RELATED: CMO Fareva opens U.S. aerosol plant, adding more than 80 jobs

Meanwhile, Fareva is also in “exclusive negotiations” to secure two additional sites from Merck & Co. and Novartis, the CMO said in a release.

The Merck plant in Mirabel, France, employs 350 workers specializing in injectable antibiotics and other sterile medicines, Fareva said. That site has the ability to expand its capacity and would act as a backup production facility for the company’s other sites.

Fareva is also angling to pick up Novartis’ plant in Unterach, Austria, which manufactures high-potency prefilled syringes, ampoules and lyophilized vials, Fareva said. The Unterach site employs 500 workers.

The major expansion in the EU comes a few years after Fareva looked to beef up its footprint in the U.S. In December 2016, Fareva opened a $40 million aerosol production facility at its Richmond, Virginia, site. Fareva said the plant has a capacity to manufacture about 100 million aerosol cans annually and would add 80 to 100 jobs to pick up the work.

According to its website, Fareva operates in 11 countries with 39 factories and employs around 12,000 workers.



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...